On August 21, 2025, Tyra Biosciences announced that the first child has been dosed in BEACH301, a Phase 2 clinical study. This study evaluates the safety and efficacy of dabogratinib (formerly TYRA-300) in children with achondroplasia, the most common form of dwarfism.
Dabogratinib is an investigational, once-daily oral FGFR3-selective inhibitor, and it is the only oral FGFR3-selective inhibitor currently in clinical development for achondroplasia. The study aims to precisely target the root cause of the condition, which is an alteration in FGFR3.
The BEACH301 study is a multicenter, open-label, dose-escalation/dose-expansion trial enrolling children aged 3 to 10 with achondroplasia. Initial results from the safety sentinel cohort are expected in the second half of 2026, providing crucial insights into the drug's profile in this patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.